Compare PAVS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVS | ENTX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 147.4M |
| IPO Year | 2018 | 2015 |
| Metric | PAVS | ENTX |
|---|---|---|
| Price | $4.03 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 11.2K | ★ 389.5K |
| Earning Date | 08-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $541.46 | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | ★ N/A | $12.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.02 | $0.91 |
| 52 Week High | $26.69 | $4.20 |
| Indicator | PAVS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 51.28 |
| Support Level | $3.86 | $2.71 |
| Resistance Level | $5.55 | $3.12 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 10.00 | 56.14 |
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.